These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18329537)

  • 1. Novel treatment approaches to fibrosis in scleroderma.
    Distler J; Distler O
    Rheum Dis Clin North Am; 2008 Feb; 34(1):145-59; vii. PubMed ID: 18329537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative therapies for systemic sclerosis.
    Ong VH; Denton CP
    Curr Opin Rheumatol; 2010 May; 22(3):264-72. PubMed ID: 20190640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and consequences of fibrosis in systemic sclerosis.
    Denton CP; Black CM; Abraham DJ
    Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status.
    Burt RK; Milanetti F
    Curr Opin Rheumatol; 2011 Nov; 23(6):519-29. PubMed ID: 21857226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic sclerosis: an update.
    Varga J
    Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pathogenic and therapeutic concepts in systemic sclerosis.
    Hügle T; Huigens CA; van Laar JM
    Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous HSCT in systemic sclerosis: a step forward.
    Farge D; Gluckman E
    Lancet; 2011 Aug; 378(9790):460-2. PubMed ID: 21777973
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunological reconstitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression.
    Bohgaki T; Atsumi T; Bohgaki M; Furusaki A; Kondo M; Sato-Matsumura KC; Abe R; Kataoka H; Horita T; Yasuda S; Amasaki Y; Nishio M; Sawada K; Shimizu H; Koike T
    J Rheumatol; 2009 Jun; 36(6):1240-8. PubMed ID: 19447934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term treatments for systemic sclerosis: what are the perspectives?].
    Mouthon L; Agard C; Garcia De La Peña-Lefebvre P; Guillevin L
    Ann Med Interne (Paris); 2002 Jun; 153(4):265-75. PubMed ID: 12218893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways as novel therapeutic targets in systemic sclerosis.
    Trojanowska M; Varga J
    Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis.
    van Laar JM; Farge D; Tyndall A
    Ann Rheum Dis; 2005 Oct; 64(10):1515. PubMed ID: 16162905
    [No Abstract]   [Full Text] [Related]  

  • 13. [Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?].
    Verrecchia F; Michel L; Keshtmand H; Wang Y; Launay D; Farge D
    Rev Med Interne; 2009 Nov; 30(11):955-62. PubMed ID: 19349102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future targets in the management of systemic sclerosis.
    Tyndall A; Matucci-Cerinic M; Müller-Ladner U
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii49-53. PubMed ID: 19487225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult stem cell treatment of scleroderma.
    Tyndall A; Furst DE
    Curr Opin Rheumatol; 2007 Nov; 19(6):604-10. PubMed ID: 17917542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic sclerosis refractory disease: from the skin to the heart.
    Almeida I; Faria R; Vita P; Vasconcelos C
    Autoimmun Rev; 2011 Sep; 10(11):693-701. PubMed ID: 21575745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying treatment in systemic sclerosis: current status.
    Quillinan NP; Denton CP
    Curr Opin Rheumatol; 2009 Nov; 21(6):636-41. PubMed ID: 19726995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phototherapy: a promising treatment option for skin sclerosis in scleroderma?
    Sunderkötter C; Kuhn A; Hunzelmann N; Beissert S
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii52-iii54. PubMed ID: 16987838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients.
    Kudo H; Jinnin M; Yamane K; Makino T; Kajihara I; Makino K; Honda N; Nakayama W; Fukushima S; Ihn H
    J Dermatol Sci; 2013 Jan; 69(1):77-80. PubMed ID: 23102713
    [No Abstract]   [Full Text] [Related]  

  • 20. [Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].
    Sicińska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):196-200. PubMed ID: 18942347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.